SPT1 Activators
SPT1 activators encompass a range of chemical compounds that indirectly bolster the functional activity of SPT1 through disparate signaling pathways. Forskolin acts by raising intracellular cAMP levels, which indirectly promotes SPT1's functional activity by activating protein kinase A (PKA). PKA, in turn, may facilitate the phosphorylation of substrates that interact with SPT1, enhancing its activity. Similarly, Phorbol 12-myristate 13-acetate (PMA) functions as a protein kinase C (PKC) activator, and the activation of PKC has the potential to enhance SPT1 activity by increasing phosphorylation within the pathway where SPT1 is implicated. The non-selective phosphodiesterase inhibitor IBMX induces a rise in intracellular cAMP by preventing its degradation, which could amplify the PKA pathway, thus potentially enhancing the activity of SPT1. Likewise, Sildenafil and Zaprinast, both PDE5 inhibitors, elevate cGMP levels, which may indirectly augment SPT1 activity by modulating signaling pathways that intersect with SPT1's regulatory mechanisms.
In concert with these activators, A23187, a calcium ionophore, increases intracellular calcium, thereby potentially enhancing SPT1's activity through calmodulin or calcium-dependent kinases that are part of SPT1's pathway. Epigallocatechin gallate (EGCG) influences kinase activity, possibly promoting the activity of SPT1 by altering phosphorylation patterns. Inhibition of PI3K by LY294002 and modulation of the MAPK pathway via PD 98059 could also indirectly enhance SPT1 activity via compensatory cellular signaling mechanisms. Furthermore, Nicotinamide riboside promotes the production of NAD+, which may enhance SPT1 function through sirtuin-mediated deacetylation of proteins within SPT1's regulatory network. Resveratrol, by activating SIRT1, could lead to similar deacetylation effects, indirectly promoting SPT1's activity. These compounds, through their targeted influence on cellular signaling, facilitate the enhancement of SPT1's functional activity without necessitating the upregulation of its expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin is a diterpene that activates adenylate cyclase, leading to an increase in cyclic AMP (cAMP) levels, which in turn activates PKA. PKA phosphorylation can enhance SPT1 activity by promoting a conformational change or altering its interaction with other proteins in its pathway. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diester of phorbol and acts as a PKC activator. Activation of PKC can lead to enhanced phosphorylation of proteins that are in the same pathway as SPT1, potentially increasing SPT1 activity or its ability to interact with other proteins or substrates. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which increases intracellular cAMP by preventing its breakdown. Elevated cAMP can augment the PKA pathway, thereby potentially enhancing the activity of SPT1 through downstream effects. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. Elevated calcium can activate calmodulin and calcium-dependent kinases, which could then enhance SPT1 activity by affecting the pathway or complex in which SPT1 operates. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that can modulate kinase activity. By influencing kinases within the signaling pathways that SPT1 is involved in, EGCG could indirectly enhance the activity of SPT1 through changes in phosphorylation patterns or allosteric effects on proteins regulating SPT1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which could shift the balance of downstream signaling pathways, including those involving SPT1. By inhibiting PI3K, LY294002 might enhance SPT1 activity via compensatory mechanisms within the cell signaling network. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that can lead to altered MAPK pathway signaling. This could result in an indirect enhancement of SPT1 activity if SPT1 is functionally linked to the MAPK pathway or if MAPK regulates proteins that interact with or modulate SPT1. | ||||||
Nicotinamide riboside | 1341-23-7 | sc-507345 | 10 mg | $411.00 | ||
Nicotinamide riboside is a precursor of NAD+ which is involved in redox reactions and can influence sirtuin activity. Sirtuins can deacetylate proteins and affect their function, which may include proteins that regulate SPT1 activity, potentially enhancing SPT1 function. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is a polyphenolic compound known to activate SIRT1. Activation of SIRT1 can lead to deacetylation of multiple proteins within signaling pathways, which could indirectly enhance SPT1 activity by modulating its interaction with other cellular proteins. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is a PDE5 inhibitor, like Sildenafil, and increases cGMP levels, which may enhance SPT1 activity by altering the cGMP-dependent signaling pathways that interact with or regulate SPT1. | ||||||